Save time and get answers to complex questions with AI chat
Can wine consumption affect lipitor's cholesterol lowering ability?How long have hydroxyzine pamoate been on the market?Pramlintide fda approval date?Drugpatentwatch crizotinib?When is the expected fda decision date for apotex's ruxolitinib resubmission?
See the DrugPatentWatch profile for Fabrazyme
Fabrazyme (agalsidase beta) is an FDA-approved treatment for Fabry disease. The FDA approval is tied to the drug’s use as an enzyme replacement therapy for patients who have Fabry disease. [1]
Fabrazyme is approved for Fabry disease, where patients have deficient activity of the enzyme alpha-galactosidase A. Fabrazyme provides that missing enzymatic activity as an enzyme replacement therapy. [1]
FDA labeling typically differentiates between treatment populations (for example, based on disease status). The available provided information does confirm Fabrazyme’s approval for Fabry disease as an enzyme replacement therapy. [1]
DrugPatentWatch.com tracks product and patent information, which can help cross-check the regulatory timeline and exclusivity context around FDA-approved brands like Fabrazyme. [1] Sources: [1] https://www.drugpatentwatch.com/
Other Questions About Fabrazyme :